tiprankstipranks
Advertisement
Advertisement

MOLN Stock Latest News

Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
RatingsMolecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
8d ago
MOLN
Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base
PremiumCompany Announcements
Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base
8d ago
6K
MOLN
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
PremiumCompany Announcements
Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma
1M ago
6K
MOLN
Molecular Partners doses first patients in MP0317 combination study
PremiumThe Fly
Molecular Partners doses first patients in MP0317 combination study
2M ago
MOLN
Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging
PremiumCompany Announcements
Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging
2M ago
6K
MOLN
Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
PremiumRatingsMolecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged
2M ago
MOLN
Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial
Premium
Company Announcements
Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial
2M ago
6K
MOLN
Molecular Partners, Orano Med doses first patient in MP0712 study
Premium
The Fly
Molecular Partners, Orano Med doses first patient in MP0712 study
2M ago
MOLN
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
PremiumCompany Announcements
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
3M ago
6K
MOLN
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
PremiumThe Fly
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
3M ago
MOLN
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
PremiumRatings
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
4M ago
MOLN
Molecular Partners Advances Radio-DARPin and Immuno-Oncology Pipeline on Solid Financial Footing in Q1 2026
PremiumCompany Announcements
Molecular Partners Advances Radio-DARPin and Immuno-Oncology Pipeline on Solid Financial Footing in Q1 2026
4M ago
6K
MOLN
Molecular Partners Showcases Nature Cancer Phase 1 Data and Advances MP0317 Into Phase 2 Cholangiocarcinoma Trial
PremiumCompany AnnouncementsMolecular Partners Showcases Nature Cancer Phase 1 Data and Advances MP0317 Into Phase 2 Cholangiocarcinoma Trial
4M ago
6K
MOLN
Molecular Partners publishes MP0317 clinical data in Nature Cancer
Premium
The Fly
Molecular Partners publishes MP0317 clinical data in Nature Cancer
4M ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
Premium
Ratings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
4M ago
MOLN
Molecular Partners announces presentation of preclinical data at AACR
PremiumThe Fly
Molecular Partners announces presentation of preclinical data at AACR
5M ago
MOLN
Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
PremiumCompany Announcements
Molecular Partners Adds Deal Veteran to Board as Shareholders Back All AGM Proposals
5M ago
6K
MOLN
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
PremiumCompany Announcements
Molecular Partners Sets 2026 AGM, Nominates Clare Fisher to Board as Long-Serving Director Steps Down
5M ago
6K
MOLN
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 3/16/2026, According to Top Analysts
6M ago
MOLN
SVCO
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
PremiumRatingsMolecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
6M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
Premium
Ratings
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
6M ago
MOLN
Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
Premium
Company Announcements
Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline
6M ago
6K
MOLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >